Close Menu

NEW YORK – Adaptive Biotechnologies today announced a partnership with AbbVie to use next-generation sequencing-based minimal residual disease testing in multiple myeloma drug trials.

Under the terms of the multi-year, global collaboration agreement, AbbVie will use Adaptive's clonoSeq assay to assess MRD status in response to venetoclax across multiple clinical trials. The partners will evaluate the depth and duration of response to venetoclax by using clonoSeq to measure and monitor MRD negativity in treated patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.